Introduction: A subgroup of lung adenocarcinoma shows neuroendocrine differentiation and expression of achaetescute family bHLH transcription factor 1 (ASCL1), common to high-grade neuroendocrine tumors, small-cell lung cancer and large cell neuroendocrine carcinoma.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide and NSCLC comprises approximately 85% of cases. 1 The major histologic subtypes of NSCLC include adenocarcinoma and squamous cell carcinoma.
Within these morphologically defined entities, extensive molecular studies revealed highly heterogeneous features with respect to genomic alterations and transcriptional profiles. [2] [3] [4] [5] In the recent WHO classification system, SCLC and largecell neuroendocrine carcinoma (LCNEC) are grouped into high-grade neuroendocrine tumors. 6 These tumors show neuroendocrine morphology and are immunostained for neuroendocrine markers, neural cell adhesion molecule 1 (NCAM1), synaptophysin (SYP), and/or chromogranin A (CHGA). 7 However, neuroendocrine differentiation is not restricted to these entities and many studies described that neuroendocrine features were also observed in a subset of adenocarcinoma. 8 However, its existence as a distinct entity or its clinical relevance remained controversial due to the lack of standard diagnostic criteria. 9 Previous studies showed that approximately 10% to 20% of lung adenocarcinomas were positively stained for the established neuroendocrine markers. 10, 11 In line with these observations, gene expression profiling from a large cohort of lung tumors identified a subset of pathologically diagnosed lung adenocarcinoma defined by high-level expression of neuroendocrine genes. 12 Molecular mechanisms involved in neuroendocrine differentiation include Notch pathway, achaete-scute family bHLH transcription factor 1 (ASCL1), and INSM transcriptional repressor 1 (INSM1). [13] [14] [15] [16] [17] [18] [19] [20] [21] Particularly, ASCL1 acts as a master regulator for pulmonary neuroendocrine cell lineage specification, and is required for a murine model of SCLC, the prototypical neuroendocrine tumor of the lung. [21] [22] [23] In agreement with the frequency of lung adenocarcinoma with neuroendocrine gene signatures, immunohistochemical studies have shown immunoreactivity for ASCL1 in 8% to 18% of lung adenocarcinoma tissue samples. 11, 12, 24 In contrast, ASCL1 protein expression is rare in lung squamous cell carcinoma. 24 Of clinical significance, it has been shown that ASCL1 target gene expression signature was predictive of shorter survival in NSCLC. 24 Also, ASCL1 co-expression gene signature defined a subgroup of lung adenocarcinoma with poor prognosis. 25 These observations might reflect differences in molecular backgrounds and responses to the standard therapy. Thus, recognition of lung adenocarcinoma with neuroendocrine differentiation based on ASCL1 expression status could be clinically important from prognostic and therapeutic viewpoints. However, clinical features of this potential entity and functional roles of ASCL1 in lung adenocarcinoma with neuroendocrine differentiation remain fragmentarily understood.
In recent years, genomic alterations, mutation profiles, DNA methylation patterns, and transcriptomic changes in NSCLC have been extensively investigated in large cohorts. 2, 3, [26] [27] [28] In parallel, genome and transcriptome analyses of large panels of NSCLC cell lines have been developed and publicly available. [29] [30] [31] Previous reports relied on cDNA microarray analyses for transcriptional profiling of NSCLC with neuroendocrine differentiation. 11, 12, 24 In this study, we investigated recent transcriptome datasets of NSCLC tissue samples analyzed by next-generation sequencing technologies. Through integrative analyses, we aimed to clarify molecular and clinical characteristics of ASCL1-positive lung adenocarcinoma. Furthermore, we examined functional roles and target genes of ASCL1 by cell culture experiments.
Materials and Methods

Public Data of NSCLC
RNA-sequencing (RNA-seq) data of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) from The Cancer Genome Atlas (TCGA) were obtained from the Genomic Data Commons Data Portal (https:// gdc-portal.nci.nih.gov). Fragments per kilobase of exon per million mapped fragments (FPKM) values from HTSeq pipeline (GDC.h38 GENCODE v22, data status as of June 1, 2016) were log 2 transformed and used for differential expression analysis. 4 RNA-seq data of 184 pathologically diagnosed NSCLC patients treated at the Uppsala University Hospital were from GSE81089. 27 Cap analysis of gene expression (CAGE) data of 97 NSCLC tissue specimens from Japanese patients treated at the Juntendo University Hospital were obtained from the DNA Data Bank of Japan (DDBJ) (JGAD00000000070). 26 Differential expression analysis was performed using edgeR. 4 DNA methylation data generated by Illumina (San Diego, California) Infinium 450K methylation array platform from the TCGA lung adenocarcinoma (LUAD) dataset were processed to obtain b values that represent DNA methylation levels. 4 Differentially methylated regions (DMRs) were identified by the Bumphunter method and the cutoff value was set as 0.1. 32 Closest genes to DMRs were annotated by matchGenes. The datasets used in this study are listed in Supplementary Table S1 .
Immunohistochemistry of Tissue Microarray
Tissue microarrays were constructed based on patients operated at the Uppsala University Hospital between 2006 and 2010 as described previously. 33 Clinical characteristics of patients are listed in Supplementary  Table 2 . The study was approved by the Uppsala Ethical Review Board. Representative tumor areas were reviewed and encircled by pathologists (P.M., H.B.) on hematoxylin-eosin stained tissue sections. Tumor cores (1 mm in diameter) were included in the tissue microarray as duplicates using a manual tissue arrayer (MTA-1, Beecher Instruments, Sun Prairie, California).
Tissue sections cut from tissue microarray blocks were mounted on adhesive slides and deparaffinized. For antigen retrieval, the slides were boiled for 4 minutes at 125 C in citrate buffer, pH6 (Lab Vision, Freemont, California). ASCL1 (clone 24B72D11.1, BD Pharmingen, San Diego, California) and programmed cell death ligand 1 (PD-L1) (clone E1L3N, Cell Signaling, Danvers, Massachusetts) antibodies were used for immunohistochemistry. Primary antibodies diluted 1:200 in UltraAb Diluent (Lab Vision) and the secondary reagent UltraVision LP HRP polymer (Lab Vision) were used. The stained slides were scanned using an Aperio ScanScope AT2 Slide Scanner (Aperio Technologies, Vista, California) with a 20Â objective to obtain high-resolution digital images. For ASCL1 immunohistochemistry, the fraction of stained tumor cells was scored as follows. 0: 0%, 1: 1%, 2: 2%-10%, 3: 11%-20%, 4: 21%-30%, 5: 31%-40%, 6: 41%-50%, 7: 51%-75%, and 8: >75%. For PD-L1 immunohistochemistry, partial or complete linear membranous PD-L1 staining was counted as positive. Protein expression levels were evaluated by calculating the H-score by multiplying the staining intensities, negative (0), weak (1), moderate (2) , and strong (3), with the percentage of stained tumor cells for each intensity giving an H-score between 0-300. Immunohistochemical evaluation was performed by H.E. and J.P. under the supervision of a lung pathologist (P.M.).
Chromatin Modifications in Lung Adenocarcinoma Cells
Chromatin immunoprecipitation (ChIP)-seq, Bisulfite (BS)-seq and RNA-seq data of lung adenocarcinoma cell lines were obtained from DDBJ. 29, 30 Mapped sequence data were visualized using Integrative Genomics Viewer. 34 
Identification of Typical Enhancers and SuperEnhancers
Super-enhancers were identified using histone 3 acetylation at lysine 27 (H3K27Ac) ChIP-seq data of 26 lung adenocarcinoma cell lines from the Database of Transcriptional Start Sites (DBTSS) according to the rank ordering of super-enhancers algorithm. 29, 30, [35] [36] [37] Neighbor enhancers were stitched together and ranked by their input-subtracted signals of H3K27Ac. Superenhancers were distinguished from typical enhancers by identifying an inflection point of H3K27Ac signal versus enhancer rank. Stitched enhancers were assigned to the transcript whose transcription start site was the nearest to the center of the stitched enhancer.
Cell Cultures
VMRC-LCD cells were obtained from JCRB Cell Bank (Osaka, Japan) and were cultured in Eagle's minimum essential medium (Life technologies, Carlsbad, California) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.
Immunoblot Analysis
Detailed procedures were described previously. 38 Mouse monoclonal anti-ASCL1 antibody was from BD Pharmingen. Mouse monoclonal antibody for a-tubulin was from Sigma-Aldrich (St. Louis, Missouri).
Cell Cycle Analysis
Cells were seeded at a density of 4 Â 10 5 per well into a 6-well plate. After 48 hours, cells were harvested, washed with phosphate-buffered saline, and fixed with 70% ethanol. After treatment with RNaseA (Sigma-Aldrich), the cells were stained with propidium iodide (Sigma-Aldrich), and flow cytometry analysis was performed.
Apoptosis Assay
Cells were seeded at a density of 4 Â 10 5 per well into a 6-well plate. After 48 hours, cells were serum starved for 24 hours, and Annexin V-stained apoptotic cells were detected using the Annexin V-FITC Apoptosis Detection Kit (BioVision, Milpitas, California).
Quantitative Reverse Transcription-Polymerase Chain Reaction
Detailed procedures were described previously. 39 Glyceraldehyde 3-phosphate dehydrogenase expression levels were used for normalization. Polymerase chain reaction (PCR) primers are shown in Supplementary Table S3 .
Knockdown of ASCL1 in VMRC-LCD Cells
Small interfering RNA (siRNA) against human ASCL1 (Silencer Select siRNA) was purchased from Life Technologies. The siRNA sequences are shown in Supplementary Table S3 . Silencer Select Negative Control No. 1 (#4390843) was used as control. VMRC-LCD cells were transfected with 20 nmol/L siRNA using Lipofectamine RNAiMAX (Life Technologies).
RNA-seq Analysis in VMRC-LCD Cells
RNA-seq reads were analyzed using CLC Genomics workbench software (Qiagen, Hilden, Germany). Reads per kilobase of exon per million mapped reads (RPKM) data were generated. Adapter sequences were removed, and read mapping was performed using the default settings of RNA-Seq analysis package. 39 
Statistical Analysis
Differences were examined by analysis of variance with Tukey's post hoc test with JMP, version 11 (SAS Institute Inc., Cary, North Carolina). p < 0.05 was considered significant.
Results
ASCL1-High Subgroup of NSCLC is More Prevalent in Adenocarcinoma Than Squamous Cell Carcinoma
Previous immunohistochemical studies described that 8% to 18% of lung adenocarcinoma tissues were positively stained for ASCL1. 11, 24 To confirm these findings, we used a tissue microarray derived from NSCLC patients operated at the Uppsala University Hospital. We could evaluate ASCL1 staining in 325 cases (224 adenocarcinomas and 101 squamous cell carcinomas), and ASCL1 expression was scored based on the fraction of stained tumor cells (Fig. 1A) . For validation purpose, we compared ASCL1 staining scores and ASCL1 transcript levels in the cases with available RNA-seq data (115 adenocarcinomas and 65 squamous cell carcinomas), and confirmed their positive correlation (r ¼ 0.45) (Supplementary Fig. S1 ). This finding indicated that mRNA expression can serve as a surrogate for protein expression.
In total, 10.8% (n ¼ 35 of 325) of patients showed positive ASCL1 protein expression (score ! 1). Notably, high ASCL1 expression (score !3, stained tumor cells !11%) was observed only in adenocarcinomas (7.1%, n ¼ 16 of 224) (Supplementary Table S2 ). These frequencies were in line with previous studies. 11, 24 To extend the analysis to large cohorts of NSCLC patients, we investigated ASCL1 transcript levels using publicly available genome-wide transcriptome datasets. 2, 3, 26, 27 First, we used the TCGA database and principal component analysis integrating the datasets of LUAD (n ¼ 533) and LUSC (n ¼ 502) based on the 2000 most variant genes clearly segregated LUAD and LUSC samples (Fig. 1B, left) . We categorized ASCL1 expression levels as high (FPKM > 50), intermediate (50 ! FPKM > 5), and low (5 ! FPKM). Consistent with the previous report, ASCL1-high tumors were more prevalent in LUAD (8.3%, n ¼ 44 of 533) and were rare in LUSC (1.4%, n ¼ 7 of 502) (Fig. 1B, right) . 24 Notably, the principal component analysis plot showed that ASCL1-high squamous cell carcinomas clustered close to adenocarcinomas (Fig. 1B, right) . We further tested correlations between ASCL1 and neuroendocrine markers among adenocarcinoma samples. ASCL1 expression levels positively correlated with those of INSM1 (r ¼ 0.46), SYP (r ¼ 0.37), CHGA (r ¼ 0.27), and NCAM1 (r ¼ 0.28), in line with the previous report (Fig. 1C ).
11
ASCL1-High Lung Adenocarcinoma is More Prevalent in Current Smokers Than Nonsmokers
Next, we explored a relationship between ASCL1 expression and smoking status in the TCGA LUAD dataset. Consistent with the previous study, ASCL1-high cases were more prevalent in current (15.7%, n ¼ 18 of 115) than reformed smokers (6.7%, n ¼ 21 of 313) or lifelong nonsmokers (2.8%, n ¼ 2 of 71) (Supplementary Fig. 2A , left). 11 Moreover, ASCL1-high cases were more frequent in males (11.4%, n ¼ 27 of 236) than females (5.1%, n ¼ 14 of 277) (Supplementary Fig. 2A, right) .
In addition to the TCGA dataset, we analyzed NSCLC dataset from the Uppsala University Hospital that included 118 adenocarcinomas and 66 squamous cell carcinomas. Consistent with the findings in the TCGA dataset, ASCL1-high (FPKM > 50) tumors were more prevalent in adenocarcinomas (5.1%, n ¼ 6 of 118) than squamous cell carcinomas (1.5%, n ¼ 1 of 66) ( Supplementary Fig. 2B , left). ASCL1-high cases were mostly found in current or ex-smokers ( Supplementary  Fig. 2B , middle). There was not a clear gender difference ( Supplementary Fig. 2B , right).
High ASCL1 Expression in Lung Adenocarcinoma is not Associated With Patient Survival
Next, we evaluated whether ASCL1 expression is associated with survival. When adenocarcinoma cases from the Uppsala cohort with available survival data (n ¼ 223) was evaluated according to protein expression levels (ASCL1 staining scores), there was no statistical difference in patient survival between ASCL1-low (score 2, stained tumor cells 10%, n ¼ 207) and ASCL1-high (score ! 3, stained tumor cells ! 11%, n ¼ 16) subgroups (p ¼ 0.68) ( Supplementary Fig. 3A ). Similar results were obtained from the TCGA LUAD dataset (n ¼ 533) and there was no prognostic difference among ASCL1-high, ASCL1-intermediate, and ASCL1-low subgroups ( Supplementary Fig. 3B ). These observations were consistent with previous reports that ASCL1 expression alone was not associated with patient survival whereas ASCL1-associated gene signatures could predict poor prognosis. 24, 25 High ASCL1 Expression is Rare in Lung Adenocarcinoma With EGFR Mutation
Mutations in KRAS and EGFR are the most common and mutually exclusive cancer drivers in lung adenocarcinoma with frequencies of 20% to 30% and 5% to 45%, respectively.
40 ASCL1-high cases were found in 9.8% (n ¼ 15 of 153) of KRAS mutation-positive patients, 0% (n ¼ 0 of 54) of EGFR mutation-positive patients, and 9.2% (n ¼ 27 of 292) of patients without KRAS or EGFR mutations. ASCL1 expression was significantly lower in EGFR mutation-positive patients (Fig. 1D, left) .
Regarding tumor suppressor genes, tumor protein p53 (TP53) and RB transcriptional corepressor 1 (RB1), we did not find statistical differences in the frequency of ASCL1-high adenocarcinoma between mutated (TP53: 8.0%, n ¼ (Fig. 1D , middle left and middle right). Notably, the frequency of ASCL1-high adenocarcinoma was significantly higher in serine/threonine kinase 11 (STK11) mutationpositive patients (40.5%, n ¼ 17 of 67) than in STK11 WT patients (5.8%, n ¼ 25 of 432) (Fig. 1D, right) .
ASCL1-High Lung Adenocarcinoma Shows Distinct Transcriptional Profiles
In addition to the RNA-seq datasets from the TCGA and Uppsala cohorts, we analyzed ASCL1 expression levels and its relationship with neuroendocrine genes using the CAGE dataset of 75 lung adenocarcinomas and 22 squamous cell carcinomas from Japanese patients treated at the Juntendo University Hospital. 26 CAGE captures the 5 0 end of capped transcripts, determines transcription start sites, and quantitatively measures transcript levels across the whole genome. 41 We compared ASCL1 expression transcribed from the main transcription start site (p1 promoter) among different histologic subtypes. Consistent with the findings in the TCGA and Uppsala cohorts, ASCL1-high (normalized tag counts > 15) cases were found in adenocarcinomas (9.3%, n ¼ 7 of 75) more frequently than in squamous cell carcinomas (4.5%, n ¼ 1 of 22) (Supplementary Fig. 4A ).
Next, we compared CAGE profiles between ASCL1-high (n ¼ 7) and low (n ¼ 53, normalized tag counts < 2) lung adenocarcinomas to identify differentially expressed genes ( Supplementary Fig. 4B and Supplementary Table 4) . As a result, 538 CAGE-defined promoters (186 p1 promoters) showed significantly higher expression in ASCL1-high adenocarcinoma cases (false discovery rate < 0.05 and log 2 fold change > 1.0). Importantly, coding genes that showed higher expression (157 p1 promoters) included those related to neuroendocrine differentiation such as INSM1, CHGA, NCAM1, calcitonin related polypeptide alpha (CALCA), gastrin-releasing peptide (GRP), and ASCL1 target genes such as ret proto-oncogene (RET) and delta-like canonical Notch ligand 3 (DLL3) (Supplementary Fig. 4B ). 11, 21, 24 Proximal-Proliferative Subtype is Predominant in ASCL1-High Lung Adenocarcinoma Lung adenocarcinomas can be separated into distinct molecular subtypes by gene expression profiling. 42 Recently, an updated nomenclature of transcriptional subtypes was proposed by TCGA, which includes terminal respiratory unit (TRU), proximal-inflammatory (PI), and proximal-proliferative (PP) subtypes. 3 We used the gene signature defined by Wilkerson et al. 42 and clustering analysis separated TCGA LUAD tumors into these molecular subtypes. Consistent with the previous report, EGFR mutation was frequent in TRU subtype whereas PP subtype was enriched for KRAS-mutated or STK11-mutated cases.
42 TP53 mutation was abundant in PI subtype ( Fig. 2A) . We explored an association of ASCL1 expression with molecular subtypes, and interestingly, most of ASCL1-high tumors were grouped into the PP subtype ( Fig. 2A) .
ASCL1-High Lung Adenocarcinoma Reveals Poor Immune Response Status
It has been recently shown that the tumor immune landscape is different among molecular subtypes of lung adenocarcinoma, and PP subtype shows lower expression levels of genes that reflect immune cell infiltration in the tumor tissue compared to TRU and PI subtypes. 43, 44 Based on the previously reported gene sets, we manually curated marker genes for each immune cell type, and included major histocompatibility complex class II (MHC II) molecules and targetable immune-related genes (programmed cell death 1 [PD-1], PD-L1, PD-L2, and Table 5) . 43, 44 Clustering analysis based on these gene signatures separated TCGA LUAD tumors into four clusters that exhibited differential expression patterns of the tested gene signatures. ASCL1-high cases were grouped into the cluster that included the majority (Fig. 2B) . This cluster was characterized by generally lower expression of immune cell markers, MHC II molecules, and immune-related genes. These results suggested that intratumoral immune cell infiltration and immune responses are relatively poor in ASCL1-high lung adenocarcinoma, which would be an obstacle to immunotherapy.
ASCL1-High Lung Adenocarcinoma is Negative for PD-L1 Immunostaining
Recently, immune checkpoint inhibitors are emerging as effective treatments for NSCLC. Immunohistochemical staining for PD-L1 is used to predict therapeutic responses of PD-1 and PD-L1 checkpoint inhibitors in the clinical setting. 45 To assess the relationship between ASCL1 and PD-L1 protein expression levels, we performed immunohistochemistry for PD-L1 in tissue microarray samples obtained from the Uppsala cohort. PD-L1 protein expression was evaluated semiquantitatively using the H-score as the product of staining intensity and percentage of stained tumor cells. (Fig. 3A) . PD-L1 positivity (H-score ! 1) was found in 38.4% of adenocarcinomas (n ¼ 84 of 219) and 51.5% of squamous cell carcinomas (n ¼ 52 of 101). Among them, high PD-L1 staining score (H-score ! 100) was noted in 21.5% of adenocarcinomas (n ¼ 47 of 219) and 36.6% of squamous cell carcinomas (n ¼ 37 of 101) ( Supplementary Fig. 5 ). For validation purpose, we compared PD-L1 staining scores and PD-L1 transcript levels in the cases with available RNA-seq data (113 adenocarcinomas and 63 squamous cell carcinomas), and confirmed their strong correlation (r ¼ 0.75) (Supplementary Fig. 5 ).
We compared PD-L1 staining scores among three subgroups with different ASCL1 protein expression levels. Interestingly, NSCLC cases with ASCL1 positivity (score ! 1) were negative for PD-L1 immunostaining except for two squamous cell carcinomas, suggesting that PD-1 and PD-L1 checkpoint inhibitors are presumably ineffective in ASCL1-positive NSCLC patients (Fig. 3B ).
ASCL1-High Lung Adenocarcinoma Shows Global DNA Hypomethylation
In addition to mutational and transcriptomic changes, epigenetic alterations constitute molecular heterogeneity of lung adenocarcinoma. 3 To dissect DNA methylation profiles associated with ASCL1 expression in lung adenocarcinoma, we used the TCGA LUAD dataset of genome-wide methylation profiling. 3 Lung adenocarcinomas with available methylation data (n ¼ 396) were categorized into ASCL1-high (FPKM > 50), ASCL1-intermediate (50 ! FPKM > 5), and ASCL1-low (5 ! FPKM) subgroups. We analyzed genome-wide distributions of b values for cytosine-phosphate-guanine (CpG) sites that represent DNA methylation status, and found a trend of global hypomethylation in ASCL1-high subgroup compared to ASCL1-intermediate or ASCL1-low subgroup (Supplementary Fig. 6 ). 4 Next, we identified 49,304 DMRs across the whole genome between ASCL1-high (n ¼ 39) and ASCL1-low (n ¼ 335) subgroups. Consistent with the observation that ASCL1-high subgroup displays global DNA hypomethylation, most of DMRs (>90%) were hypomethylated in ASCL1-high subgroup (Supplementary Table 6 ).
ASCL1 is Highly Activated and Associated With Super-Enhancers in a Subset of Lung Adenocarcinoma Cell Lines
To further characterize the molecular background of ASCL1-high lung adenocarcinoma, we used the DBTSS which provides integrative multi-omics datasets of 26 different lung adenocarcinoma cell lines including RNAseq, BS-seq, and histone 3 modifications. 29, 30 First, we compared gene expression patterns in these 26 cell lines based on RNA-seq data. Multidimensional scaling plot based on the 5000 most variant genes illustrated the diversity of gene expression profiles among 26 cell lines (Fig. 4A) . Two cell lines, VMRC-LCD and PC-7, with the most divergent transcriptional patterns were the only ones that express high levels of endogenous ASCL1. In both cell lines, high transcript levels (RNA-seq) and enrichment of active histone marks (H3K27Ac and H3K4me3 ChIP peaks) at ASCL1 locus were identified. These were absent in 24 other cell lines such as A549 (KRAS mutation-positive), PC-9 (EGFR mutationpositive), and LC-2/ad (RET fusion-positive) cells (Fig. 4B) . 29, 30 We further investigated DNA methylation status in these cell lines, and analyzed BS-seq data that provide single-base resolution of methylated cytosines in genomic DNA. BS-seq signals were relatively low at ASCL1 locus in VMRC-LCD and PC-7, suggesting that differential ASCL1 expression is regulated by DNA methylation (Fig. 4B) .
To explore an association between ASCL1 expression and DNA methylation levels in lung adenocarcinoma tissue samples, we used the TCGA LUAD dataset and (two CpG sites) or within the first exon (eight CpG sites) ( Supplementary Fig. 7A ). We found that ASCL1 expression levels were inversely correlated with b values for these CpG sites, and methylation levels were remarkably low in nearly all samples of ASCL1-high and ASCL1-intermediate subgroups, suggesting that ASCL1 expression is closely related to DNA hypomethylation in lung adenocarcinomas ( Supplementary Fig. 7B ). Super-enhancers characterized by enrichment of master transcription factors and high levels of H3K27Ac signals play an essential role for cell lineage specification. [35] [36] [37] According to the rank ordering of Fig. S8 ). Key transcription factors involved in lung epithelial cell differentiation, forkhead box A2 (FOXA2), and NK2 homeobox 1 (NKX2-1) are also indicated.
super-enhancers algorithm, super-enhancers in 26 cell lines were determined by ranking their input-subtracted signals of H3K27Ac. We found that ASCL1 and INSM1 were associated with super-enhancers in VMRC-LCD and PC-7, while not meeting the criteria for super-enhancers in any other cell ( Fig. 4C and Supplementary Fig. 8 ).
We further determined super-enhancer-associated transcription factors in 26 Table 7) , and found that those of VMRC-LCD and PC-7 were largely overlapping, suggesting that ASCL1-high cell lines have common transcriptional regulatory networks (Supplementary Table 7) . 46 In fact, superenhancer distributions could explain differential expression of other functionally important transcription factors including forkhead box A2 (FOXA2) and NKX2-1 (alias thyroid transcription factor 1 [TTF-1]) ( Fig. 4C and Supplementary Fig. 8 ). 47 
Functional Roles of ASCL1 in VMRC-LCD Cells
To evaluate functional roles of ASCL1, we transfected VMRC-LCD cells with two different ASCL1 siRNAs (siASCL1 #1 and #2) and negative control. Efficient knockdown was confirmed at the protein level by immunoblotting (Fig. 5A) . ASCL1 knockdown by either siRNA inhibited cell proliferation (Fig. 5B ) and cell cycle analysis revealed an increase in G2/M fraction in agreement with the previous report that showed G2/M cell cycle arrest following ASCL1 silencing in lung cancer cells (Fig. 5C) . 17, 18 Furthermore, in the condition of serum deprivation, Annexin V-positive apoptotic cell fraction increased following siASCL1 treatment compared to negative control, suggesting a role of ASCL1 to promote cell survival (Fig. 5D ).
ASCL1 Suppression Preferentially DownRegulates Super-Enhancer-Associated Genes in VMRC-LCD Cells
To explore genes regulated by ASCL1, we performed RNA-seq analysis of VMRC-LCD cells treated with ASCL1 siRNAs. Using the thresholds of RPKM greater than 2 and log 2 fold change greater than 0.5 or less than -0.5, we found that 302 and 357 genes were commonly upregulated and down-regulated, respectively, by both #1 and #2 siRNAs for ASCL1 (Fig. 6A and Supplementary Table 8 ). The genes commonly down-regulated by siASCL1 #1 and #2 included previously identified ASCL1 target genes such as DLL3, LFNG, RET, and MYCL. 11, 21, 24 To validate the result of RNA-seq, we performed quantitative reverse transcription-PCR for these genes. Consistently, ASCL1 silencing by two different ASCL1 siRNAs suppressed their expression, supporting that ASCL1 is involved in transcriptional regulations of Notch signaling-related molecules (DLL3 and LFNG) and oncogenes (RET and MYCL) (Fig. 6B) .
Next, we performed gene ontology analysis and found that commonly down-regulated genes were associated with biological process term of "negative regulation of Notch signaling pathway involved in somitogenesis" (Fig. 6C) . Considering that ASCL1 expression is negatively regulated by Notch signaling, this result suggested a possible regulatory loop. [13] [14] [15] Accumulation of master transcription factors and other transcriptional regulators including Mediator complex in super-enhancer regions leads to expression of genes that define cell identity. [35] [36] [37] Importantly, our RNA-seq result showed that ASCL1 knockdown selectively and strongly suppressed the genes associated with super-enhancers in VMRC-LCD cells in contrast with the modest effect on typical enhancer-associated genes ( Fig. 6D and Supplementary Fig. 9 ). These results were consistent with the previous observations showing predominant binding of ASCL1 to distal enhancer regions during neurogenesis and enrichment of ASCL1-binding sites in super-enhancer regions in SCLC cell lines. 21, 48 Taken together, ASCL1 might act as a master regulator to control super-enhancer-mediated transcriptional programs to define cell identity.
To further explore clinically relevant ASCL1 target genes, we also extracted 423 genes whose expression levels were correlated with that of ASCL1 (Spearman's r > 0.3) in TCGA LUAD tumors (Supplementary Table 8) , and compared them with 357 genes commonly downregulated by siASCL1 #1 and #2 in VMRC-LCD cells. As a result, we identified 24 clinically relevant ASCL1-regulated genes that included RET, MYCL, DLL3, HES6, CALCA, and CALCB (Supplementary Table 8 ).
Discussion
In this study, we unraveled functional roles and target genes of ASCL1 and suggested that ASCL1 acts as a master regulator of super-enhancer-mediated transcriptional programs. We further showed that approximately 10% of lung adenocarcinomas showed high ASCL1 expression among the TCGA, Uppsala, and Japanese cohorts, in line with previous studies that showed ASCL1 immunoreactivity in 8% to 18% of lung adenocarcinomas. 11, 24 Taken together, we believe that ASCL1- positive adenocarcinoma represents a distinct molecular subtype that deserves further attention. Based on histologic and immunohistochemical parameters, lung adenocarcinomas can be distinguished from neuroendocrine tumors that include LCNEC and SCLC. 2, 3, 26, 27 Although high expression of ASCL1 is also observed in the majority of SCLC, we noted molecular differences between SCLC and ASCL1-positive adenocarcinoma. One important difference is the frequencies of TP53 and RB1 mutations, which were around 50% and less than 5%, respectively, in ASCL1-high adenocarcinomas in our study, whereas mutation frequencies of both TP53 and RB1 are nearly 100% in SCLC. 14, 15, 46 Thus, TP53 and RB1 mutations are not seemingly associated with ASCL1 expression in lung adenocarcinoma. Another difference is the proportion of KRAS mutation in ASCL1-high adenocarcinoma, which is rare in SCLC. 14, 15 One possible scenario for coexistence of KRAS mutation and ASCL1 expression is that a subset of KRAS-mutated adenocarcinomas might originate from pulmonary neuroendocrine cells. Another possibility is that a subset of KRAS-mutated adenocarcinomas might acquire growth advantage by ASCL1 expression. In analogy, neuroendocrine differentiation and SCLC transformation have been suggested as a mechanism for drug resistance in EGFR-mutated lung adenocarcinomas treated with EGFR tyrosine kinase inhibitors. 14 It has been previously postulated that NSCLC with neuroendocrine differentiation might transform to highgrade neuroendocrine tumors, and ASCL1-positive lung adenocarcinoma may serve as a precursor lesion for LCNEC or SCLC. Given that genetic alterations in TP53 and RB1 are frequent in LCNEC and are found in almost all SCLC cases, additional mutations of TP53 and/or RB1 occurring in ASCL1-positive lung adenocarcinomas presumably give rise to high-grade neuroendocrine tumors as suggested previously. 14, 49 Interestingly, a recent study identified two genomic subgroups of LCNEC: TP53-mutated, STK11-mutated, ASCL1-high type I LCNEC and TP53-mutated, RB1-mutated, ASCL1-low type II LCNEC. 50 Taken together with our finding that ASCL1-high lung adenocarcinoma shows high STK11 mutation and low RB1 mutation frequencies, ASCL1-high lung adenocarcinoma might be closely associated with type I LCNEC. Further validation with different tumor cohorts is necessary to confirm such an assumption.
The unique molecular features of ASCL1-positive adenocarcinoma might be of therapeutic relevance in the era of precision medicine. This is of particular importance for adenocarcinomas without targetable cancer driver mutations. Our study confirmed the previous concept that ASCL1 expression is associated with RET tyrosine kinase transactivation. 11 Thus, the already approved small synthetic RET inhibitor vandetanib might represent a conceptual treatment option in ASCL1-positive adenocarcinoma. Furthermore, we identified that Notch ligand DLL3 is overexpressed in ASCL1-high adenocarcinoma. This is in homology to DLL3 transactivation by ASCL1 in SCLC. DLL3-targeting agents such as rovalpituzumab tesirine are emerging as promising therapeutic options for SCLC and could be of value also for ASCL1-positive adenocarcinoma. 51 Given that tumorigenic mechanisms mediated by ASCL1 are common between ASCL1-positive adenocarcinoma and SCLC, such novel therapeutic options for SCLC would be applicable for ASCL1-positive adenocarcinoma.
Today, it is accepted that the immune system plays a significant role in cancer development and immune modulatory treatment options are integrated in the therapy of lung cancer. Therefore, we evaluated the immune context of ASCL1-high lung adenocarcinomas. Interestingly, these tumors seemed to present a distinct group on the immunologic level. They appeared to poorly provoke immune responses, reflected by low expression levels of immune cell markers and immune modulators in the tumor tissue. Furthermore, none of the ASCL1-positive adenocarcinomas showed relevant PD-L1 expression. This is different from SCLC and LCNEC, where the proportion of PD-L1-positive samples ranges from 15% to 21%. 52, 53 As such, it can be anticipated that ASCL1-positive adenocarcinomas with low immune response status and absence of PD-L1 expression are unlikely to respond to the current therapy with checkpoint inhibitors.
In conclusion, our results suggested that ASCL1 expression defines a distinct subgroup of lung adenocarcinoma representing unique clinical and molecular features with therapeutic implications.
